Therapeutic effect of bimatoprost in thyroid-associated ophthalmopathy

Therapeutic effect of bimatoprost in thyroid-associated ophthalmopathy - Treatment of bimatoprost in thyroid-associated ophthalmopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018580

Enrollment

Registered

2015-08-10

Start date

2015-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid-associated ophthalmopathy

Interventions

Period:One year Drug:Topical bimatoprost Number of dose:Once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients of Shiga University of Medical Science Hospital with proptosis in thyroid-associated ophthalmopathy that are examined by MRI

Exclusion criteria

Exclusion criteria: An infant, a pregnant woman, a lactating woman

Design outcomes

Primary

Measure	Time frame
Variation on a value of proptosis 3, 6, 9, 12 months after treatment	—

Secondary

Measure	Time frame
Variation on a volume of orbital fatty tissue 3, 6, 9, 12 months after treatment	—

Countries

Japan

Contacts

Public ContactTomoaki Higashiyama

Shiga University of Medical Science Department of Ophthalmology

higashi@belle.shiga-med.ac.jp0775482276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026